JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.